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ABSTRACT
The Ability of Novel Phage to Infect Virulent
Bacillus anthracis Isolates
Hyrum Smith Shumway III
Department of Microbiology and Molecular Biology, BYU
Master of Science
Bacillus anthracis is a soil dwelling microbe with pronounced pathogenic potential.
Historically, anthrax has infected livestock and man. In the modern-age, anthrax is a bioterrorism
concern with major incidents every decade. While the threat of large scale attacks is currently
viewed as unlikely, the threat is consistent and constant. Current methods to defend against such
an attack focus on antibiotics and containment of public panic. Antibiotic resistance, while not
currently an issue for anthrax, could easily become so with genetically engineered weaponized
strains created by rogue states or independent actors.
This project evolved from collaborations between the Grose lab and the Robison lab, both
housed in the Microbiology and Molecular Biology Department at Brigham Young University in
Provo, Utah. Two undergraduates in the Grose lab isolated 23 genetically distinct phage that
infect the non-pathogenic Bacillus anthracis Sterne strain. Results from spot testing on a diverse
library of 11 fully virulent strains that represent the extant genetic diversity of pathogenic B.
anthracis in BYU’s BSL-3 facility give credence to the idea that phage could be useful in
containing this pathogen.
Phage were isolated from environmental samples using enrichment culture, high titer
lysates of isolated phage were created, and differential assays were performed. Experiments to
show phage differences included electron microscopy, restriction digests, and spot testing using
different isolates of B. anthracis. These data identified several novel phage that could infect a
wide variety of virulent B. anthracis isolates. Preliminary results also showed most of these
phage to be different both morphologically and genetically.We propose that phage therapy
deserves further research, public awareness, and increased understanding for governmental
regulatory awareness.

Keywords: Phage, pathogenic, anthrax, Bacillus anthracis, infection, treatment, bioterrorism,
livestock, weaponized, spot testing, antibiotic resistance, plaque, microbe
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BACKGROUND
Bacteriophage
Phage Background
Bacteriophage, or phage, are viruses than infect bacteria (Abedon, 2009). Phage are
estimated to be over 3.5 billion years old and represent one of the most common and most
biologically diverse entities on earth (H.-W. Ackermann, 1998). Phage are incredible biological
tools which have been used as therapeutics to treat bacterial infections and as instrumental
research tools. Phage helped elucidate DNA as the genetic material in the landmark experiments
of Martha Chase (Chase, 1952; McCallin et al., 2013). Throughout millennia, ancient religious
texts of Jews, Hindus, and Christians all encouraged specific ritual washings. Phage may have
been important in ancient therapeutic medicine, with people bathing in special bodies of water
known for healing, such as the Ganges River in India which has been shown to host therapeutic
phage (Khairnar, 2016). Fredrick Twort described and isolated a filterable agent capable of
lysing bacteria, and later Felix D’Herelle extensively studied the bacteriophage and showed the
therapeutic usefulness of phage in treating illness, especially for patients plagued by dysentery
(Doore, Schrad, Dean, Dover, & Parent, 2018; Dublanchet & Bourne, 2007; Gillis & Mahillon,
2014). Phage truly hold great promise in future research as model organisms for molecular
biologists, as therapeutics to treat disease, and as a source of novel discoveries related to viral
life.
Host Interaction
The two major life states for phage are either lytic or lysogenic. Other intermediate states
exist besides lytic and lysogenic, but historically these have been the most significant states
associated with the lifecycle of phage (Schuch & Fischetti, 2009). The lysogenic cycle describes
1

phage ability to insert their genome into a bacterial host chromosome and become a prophage.
The lytic cycle describes the capacity to immediately cause a productive infection in which they
use the cell’s resources to replicate themselves, lyse the cell, and find new hosts. (Condition &
Bacteriophages, 1953). A lytic cycle will destroy large numbers of bacteria while producing even
larger numbers of viral progeny.
The lytic cycle occurs in two steps with early genes being expressed that push the cell to
upregulate phage replication. When the cell is full of assembled phage, the next step is to express
late genes which cause the lytic reaction of viral burst through lysins, holins, and murein
inhibitors (Wittebole, De Roock, & Opal, 2013). Much of phage research has been done in gram
negative systems. Much less work in the lifecycle and regulation of lytic versus lysogenic phage
has been done in gram positive bacteria (Obregón, García, López, & García, 2003).
Figure 1 depicts the lytic vs lysogenic cycle. Phage can also cause horizontal gene
transfer (HGT), which is the transfer of genetic material between bacteria. This often
complicates genetic tree analyses (Wittebole et al., 2013). HGT can be mediated by conjugation
(via sex pili), transduction (through phage) and transformation (the direct uptake of exogenous
DNA). Transduction can be either general (any part of a bacterial genome) or specialized
(specific parts of a chromosome only) (Gillis & Mahillon, 2014). Multiple transducing events
over time can dramatically change the genome of some bacteria. However, this process is much
less important in B. anthracis as this organism spends most of its time as a spore, which is
metabolically inert and incapable of viral replication. (Paul Keim et al., 2004; Schuch &
Fischetti, 2009).
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Figure 1. Differences between the lytic and lysogenic cycle for phage infection of bacteria. 1:
Insertion of phage DNA, 2: Phage DNA circularizes. Next, the phage will cause a lytic or lysogenic
infection. For lytic cycle, 3.1 shows progeny virus manufacture and 4.1 lysis. For lysogenic cycle, 3.2
depicts viral insertion of DNA forming a prophage, and 4.2 replication of DNA copying the prophage
as well, 5 depicts a prophage excising from the bacterial genome.

Early Phage History
Phage therapy is as contentious a subject today as it was almost one hundred years ago
when the first clinical study of phage therapy was published in 1921. This involved the direct
injection of phage into staphylococcal boils (Deresinski, 2009). Some believe that the first
example of phage therapy occurred in 1919 when an oral lysate was used to treat dysentery (Gill,
Franco, & Hancock, 2015; Kutter et al., 2010; Wittebole et al., 2013). Many of these reports
were not respected by the wider scientific community as the investigators failed to use good
experimental technique with double-blind controls and many such “trials” were simply reports of
a single clinician’s administration of phage to treat a disease. Early phage therapy treatments
were noted for their frequent clinical inconsistencies between different clinicians and scientists
across borders. It is believed that lack of quality control and the technical expertise to prepare
3

stable lysates were likely the main reasons why some clinicians were not able to replicate
findings performed by other groups halfway around the world in early phage therapy trials.
Often, investigators would find themselves obstructed by language barriers, as microbiologists
could be in Brazil attempting to exchange data and results with scientists in Egypt, England, or
Germany. Of commercial production of lysates D’Herelle stated, “On the whole, none of the
preparations on the market is capable of effecting recovery from infectious disease” (Dublanchet
& Bourne, 2007; Henein, 2013). A major reason why phage lysates failed is likely due to this
premature commercialization of products that were not ready for public use or proven for clinical
efficacy.
While the United States had started a Food and Drug Administration (FDA) a decade
before phage therapy, it was mostly concerned with branding issues and adulterated products in
the food industry and the medical field was not highly regulated. It was not until 1938 that a
thorough pre-market review measure was passed in the legislature and added significant
regulatory powers to the FDA (Shulman, 2013). These early pre-market reviews from the
regulations of 1938 are the backbone of current FDA clinical trials.
With the advent of administrable antimicrobials in the 1930s, the antimicrobial age was
born (Kutter et al., 2010). So confident were clinicians in the 1970s and 1980s, that it was
believed by many, that a post infectious disease state had been achieved (Henein, 2013). With
the rise of antibiotics, phage grew out of favor with the Western world, as they appeared to be
much less efficacious than antibiotics. Proponents of antibiotics and phage recognized that
administering antibiotics kills commensals and pathogens alike (Kutter et al., 2010). As we look
forward to today, it is clear than antibiotics have serious side effects much more substantial than
the loss of beneficial intestinal commensals. Antibiotic overuse has led to widespread resistance.
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Phage therapy while dismissed a hundred years ago, is experiencing a remarkable return to
clinics, scientific benches, and regulatory awareness (Brüssow, 2012; Deresinski, 2009;
McCallin et al., 2013; Ozkan et al., 2016).
Phage Therapy East to West
Phage research was present in the US in the 20th century, but it was an incredibly specific
niche and an understudied scientific expertise. However, in the East, within Georgia, India,
Russia, and to some extent France, phage work was much more well regarded, accepted, and
practiced (Kutter et al., 2010; Sybesma et al., 2016). The Eliava Institute in Georgia has, for
decades, kept a phage library of different cocktails of phage that can be used to treat a myriad of
diseases. Libraries such as this have been essential in jumpstarting research into this area in the
West. Clinicians can order specific phage for scientific investigation and occasionally U.S.
doctors have prescribed phage. In addition, medical tourism is promoted by a California
company to bring US, Australian, and European citizens to the Republic of Georgia for phage
treatment (Kutter et al., 2010). Another institute that perhaps rivals Eliava is the Hirszfeld
Institute in Poland. The institute has developed a world renown reputation for treating urinary
tract infections, septicemia, Shigella infections, and various wound infections, including
furunculosis (Kutter et al., 2010; Sulakvelidze, 2001).
Libraries such as those kept at the Eliava Institute will be essential for later regulatory
frameworks. Efficacious cocktails could be created from phage in large phage libraries, where all
phage deposited had passed regulatory approval (Mirzaei & Nilsson, 2015). In addition to
“simple” product to market regulation from the FDA, there is little (Sulakvelidze, 2001) or no
insurance coverage for phage treatment. It will be essential to prove to global insurance
exchanges and national insurance companies that phage treatment is an acceptable course of
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treatment on its own, or as an adjunct therapy (Gill et al., 2015; Torres-Barceló & Hochberg,
2016a). Phage therapy may work synergistically with antibiotics. It is believed that as the
bacteria respond to an antibiotic, they may upregulate phage receptors, and when bacteria
respond to phage, efflux pump action may be downregulated (Torres-Barceló & Hochberg,
2016a).
Currently, the regulatory framework around phage use in the US is still being formed
(Bassetti et al., 2017; Chan, Abedon, & Loc-Carrillo, 2013; Henein, 2013). The sooner the
private sector, academia, and government entities can work together on this issue, the sooner
phage therapy may be employed to help a worldwide infectious disease problem. In the
developed world (US and EU), 50,000 citizens die each year from antibiotic-resistant infections
(Torres-Barceló & Hochberg, 2016a). Bringing a new drug to market now costs between $400800 million and can go as high as $1 billion. Since phage are so new to the regulatory scene,
especially in the West, it is unclear if the cost will be lower and how the phage lysates will be
protected by patents (Henein, 2013). Many questions remain as to how and when phage therapy
will become a clinical reality, but it is clear that much effort remains in boosting public
awareness, performing private research, and defining overall regulations.
Phage Therapy Successes
Phage therapy success can be seen by the increased phage vision that informed scientific
investigators, public health officials, government regulators, and private parties now hold in
comparison to two decades ago. With new challenges, such as antibiotic resistant bacteria, come
new solutions and new opportunities. Phage therapy would probably not be considered in the
current environment, were it not for the modern infectious disease crisis. The first double-blind
experiment with phage only just occurred in the US less than a decade ago (Rhoads, 2009;
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Wittebole et al., 2013). The use of phage to decrease food-borne illnesses in ready-to-eat food
preparations have been approved by FDA and used to prevent illnesses caused by Listeria
monocytogenes and Salmonella (Henein, 2013; Torres-Barceló & Hochberg, 2016a). Current
research is expanding towards the use of phage to treat fresh produce that may be contaminated
with E. coli as well (Snyder, Perry, & Yousef, 2016).
Phage therapy would be especially important if it could be used to curb infections caused
by multi-drug resistant strains of bacteria that boast high mortality rates such as carbapenemresistant Enterobacteriaceae (CRE), P. aeruginosa and S. aureus. Research is ongoing but there
is potential for both clinicians and patients to be optimistic, as many phage-resistant strains are
susceptible to antibiotics and many antibiotic-resistant bacteria are susceptible to phage. It
appears that the fitness of bacteria may be decreased when they are fighting a “two-front” war
against multiple phage and multiple antibiotics. The susceptibility profiles of bacteria to phage
and antibiotics are unrelated. Most antibiotic-resistant strains have been shown to be highly
susceptible to phage. (Allen, Trachsel, Looft, & Casey, 2014; Ozkan et al., 2016; Torres-Barceló
& Hochberg, 2016a).
As phage possess incredible specificity to their host, phage therapy is only possible if you
have a phage specific to your target bacterium. With ingenuity and imagination, many diseases
that have a clear etiology will be helped by increased phage work and phage awareness. A new
“golden age” of microbiology may ensue as phage specific for known disease agents are
discovered.
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Anthrax
History of anthrax
Anthrax has been feared for centuries, from Roman poets (Virgil) to Egyptian Pharaohs
(Akhenaten) to ancient medieval monks and 19th century English drovers and wool workers
(Monds & O’Toole, 2009; Schwartz, 2009; Van Ert et al., 2007). The same strains that might
have been involved in Exodus chapter nine, that caused boils and death of livestock, could still
be around today, as spores are resistant to heat, desiccation, UV light, gamma radiation, and
many disinfectants (Sternbach, 2003). Anthrax is generally a disease of livestock, but much of
human existence was spent in close proximity to animals and animal products, and exposure
often led to cutaneous anthrax, or gastrointestinal anthrax if contaminated meat was ingested.
Anthrax did not die out in the industrial age, but became a serious concern for the wool industry,
so much so that pulmonary anthrax was termed “woolsorters disease” (Pilo & Frey, 2011;
Schofield et al., 2013). Anthrax exposure is still an occupational hazard for agricultural workers
in developing countries, tanners, laboratory workers, and soldiers (Craft, Lee, & Rowlinson,
2014; Lekota et al., 2016). Currently, anthrax is not endemic in most of the developed world due
to early large-scale control efforts. However, anthrax is endemic for much of South and Central
Asia, Afghanistan, Bangladesh, India, Iran, Pakistan, Kazakhstan, Kyrgzstan, Turkey, and the
Republic of Georgia (Price et al., 2012).
Discovery of anthrax
Robert Koch is credited with the discovery of the cause of anthrax in 1876, showing
definitively through his postulates that the disease was caused by a single etiological agent. Koch
worked with B. anthracis for much of his career, and made discoveries in the life cycle and
sporulation of this organism (Gillis & Mahillon, 2014). A research rivalry developed between
8

Koch in Germany and Louis Pasteur in France. Pasteur extended animal experiments,
definitively illustrating that immunity could be induced with a live attenuated vaccine (Fouet,
2001). Pasteur even hypothesized that B. anthracis could be carried by earthworms, an astute
observation with the little resources he had. Earthworms have since been implicated as
environmental reservoirs of B. anthracis (Schuch & Fischetti, 2009).
Morphology
B. anthracis can form an especially robust endospore and like most spore formers, is
gram positive. B. anthracis is non-motile, non-hemolytic, negative for phospholipase C
production, and sensitive to the gamma phage and to penicillin (Klee et al., 2006; Rao, Mohan,
& Atreya, 2010). Colony morphology and capsule staining, in addition to the other factors listed,
are tests that can help distinguish B. anthracis from other Bacillus species. (Pilo & Frey, 2011)
B. anthracis is also closely related to B. thuringiensis, notable for its use as a natural insecticide,
and B. cereus which is a common cause of human food poisoning. B. anthracis, B. cereus, and B.
thuringiensis are members of a unique clade. Of these three closely related strains, B. anthracis
is the most monophyletic (P Keim et al., 2000, 2000; Wang & Ash, 2015). Despite similar
genetics, the phylogenetics and pathogenicity do differ among sister strains.
Sporulation
B. anthracis is monophyletic because rather than existing as a constantly replicating
vegetative cell, it is found mostly as a dormant spore. Since a spore is metabolically inert, the
organism does not mutate at the same rates of other species (Paul Keim et al., 2004). The spore is
extremely hardy, even when compared to other endospores, as it also has an extra layer termed
the exosporium. However, B. anthracis cells are less hardy overall than other Bacillus species as
their vegetative state is unstable and survives poorly in the environment without the help of
9

lysogenic phage which affect sporulation, growth in worms, and growth in the wider
environment (Ganz et al., 2014; Gillis & Mahillon, 2014; Koehler, 2009; Schuch & Fischetti,
2009). B. anthracis spores are about 1 μM in diameter, and once ingested by macrophages, can
remain dormant for indefinite periods of time; a hundred days or more has been seen in human
primate studies. For recent outbreaks such as the Sverdlovsk incident in Russia in 1979, 2-43
days was the time range between infection and appearance of symptoms (Toole et al., 2002).
Pathogenicity of anthrax
Anthrax is transmitted by three routes, causing the following types of diseases: 1.
Cutaneous, 2. Gastrointestinal, and 3. Pulmonary or inhalational. A fourth route is markedly
more severe than cutaneous anthrax, and is termed injection anthrax, occurring mostly in drug
users employing needles. This is a new public health hazard and the term has been employed for
less than two decades due to differential changes in drug use across the globe. It was determined
that the heroin supply was being diluted with crushed bone (likely from infected animals) in
Afghanistan. As Afghanistan produces over 90% of the world’s heroin, it soon became a global
public health crisis (Price et al., 2012).
B. anthracis is only pathogenic if it has both virulence plasmids. Plasmid pX01 (174 kbp)
encodes for the toxin genes (peg, lef, cya) and plasmid pX02 (95 kbp) holds the genetic material
for capsule synthesis (capA, capB, capC) (Paul Keim et al., 1997; Pilo & Frey, 2011). The B.
anthracis Sterne strain is non-pathogenic as it does not have the pX02 plasmid. Without this
plasmid, the Sterne strain cannot produce the capsule and therefore is not pathogenic (Cataldi,
Mock, & Bentancor, 2000).
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Symptoms and Treatment
Early infection with B. anthracis will cause overall malaise at first, while the organism is
setting up a systemic infection and shutting down the innate immune system. Symptoms may
include coughing, headache, vomiting, chills, weakness, and abdominal pain. In late stages of
infection, which occur suddenly, fever, sweating, and shock can quickly ensue with pronounced
lymphadenopathy and possible hypoxia. The cardiovascular system and liver are prominently
targeted by the toxins which can cause organ failure and death. Fifty percent of patients may also
exhibit symptoms of meningitis. (Liu, Moayeri, & Leppla, 2014; Toole et al., 2002). Treatment
of anthrax with antibiotics such as, ciprofloxacin, vancomycin, penicillin, doxycycline, or
erythromycin, will kill the bacteria, but it will not stop toxins already present in the body so
death can still ensue. Current research is investigating small interfering molecules that may block
some of the harmful effects of the lethal factor (LF) and edema factor (EF) toxin moieties (Liu et
al., 2014). As some penicillin-resistant strains of B. anthracis have been found in nature,
ciprofloxacin is the preferred treatment (Bossi et al., 2006).
Anthrax in Bioterrorism and Biowarfare
Anthrax was a major concern for the middle part of the 20th century. England, Russia,
Germany, Japan, and the United States all had thriving bioweapon research programs. An
anthrax attack for bioterrorism is believed to be a credible and deadly threat to national security.
Anthrax spores are very hardy and relatively easy to manufacture, mill, and statically charge for
weaponization.
It is believed that 50 kg of concentrated B. anthracis spores released over a city of 5
million would kill 100,000 and sicken a quarter million, and under ideal weather conditions,
these numbers could increase by one log. If the payload was doubled to 100kg, the death toll
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would equal that of a hydrogen bomb. (Bossi et al., 2006; Toole et al., 2002). This would also
cause massive public panic and shut down many public and private services. Bioterrorism can
produce huge casualties, but it is also a type of psychological warfare, in that it can be used to
break a nation’s trust in the systems that they rely upon for daily life such as transportation
networks, water systems, and hospitals. Inhalational anthrax can be infectious with anywhere
from 8-50,000 spores. The LD50 for these spores is estimated to be between 2,500 and 50,000.
Many people may require much less, as primate data suggests a mere 1-3 spores is capable of
causing serious infection (Toole et al., 2002).
Bioterrorism is not to be dreaded every day, but nations should be prepared. As the 20th
century came to a close, few large-scale bioterrorism attacks had been committed in the public’s
recent short-term memory. The bioterror threat was felt to be overstated and emergency
preparedness budgets were not popular and perennially cut (Craft et al., 2014). The 2001 anthrax
letter attacks increased federal funding substantially, but this has mostly disappeared as no new
attacks have been reported (Gillis & Mahillon, 2014; Van Ert et al., 2007). A new challenge has
awakened in America with overregulation of scientific laboratories dealing with BSL-3 agents.
Due to the increased reporting, training, and cost of running these laboratories, many labs are not
currently situated to do BSL-3 work. When the barriers to entry for BSL-3 work are too great, it
places individuals and nations at risk. When we overprotect negligent agent release by excessive
and burdensome barriers, the only thing that happens is less research that can help mitigate the
effects of the next bioterrorism event (Wurtz, Grobusch, & Raoult, 2014). All types of research
that are not offensive bioterrorism research, should be allowed and encouraged without
overburdening regulation, including phage therapy (Barras & Greub, 2014; Riedel, 2004).
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INTRODUCTION
B. anthracis phage therapy
Known phage infecting B. anthracis
Within a decade of the introduction of phage therapy in 1919, work was performed by
D’Herelle in 1929 to combat anthrax in mice with phage (Walther, 2003). This work, although
laudable, yielded no scientific record of clinical significance. Pasteur had already shown how to
immunize cows against anthrax with a live vaccine decades earlier (Letarov, Biryukova,
Epremyan, Shevelev, & Letarov, 2016). In 1951, phage typing started with the isolation of the
Bacillus phage gamma. The gamma phage was highly specific with only a few strains lysed that
were not B. anthracis. Notable exceptions to this rule were B. cereus, isolates ATCC 4342 and
NCTC 1651, which the gamma phage did successfully infect. (Sozhamannan et al., 2008). In
addition, the gamma phage, while lysing some B. cereus strains, was also unable to lyse some
very specific B. anthracis strains. The gamma phage was used as one of the many diagnostics to
identify B. anthracis and is believed to be over 95% accurate as a diagnostic test, which is above
United States Army Medical Research Institute of Infectious Disease (USAMRIID) requirements
(Abshire, Brown, & Ezzell, 2005).
The protein conferring lysis to the gamma phage was termed PlyG. Later, another
lysogenic phage Ba02 yielded another lysin termed PlyL. PlyL and PlyG endolysins have two
domains: a cleavage domain and a recognition domain. It is hypothesized that both endolysin’s
recognition domains attach to molecules covalently bound to peptidoglycan (Ganguly et al.,
2013). The gamma phage is a Siphoviridae virus as it is a tailed phage with a non-contractile tail
(Morimoto;Shiomi, 1975). In the former Soviet Union, another phage, bacteriophage Fah, was
used as a diagnostic tool in place of the gamma phage that is so well characterized in Western
13

scientific literature. Fah is strictly lytic and its genetic origins are unknown. Prophage similar to
it are found in isolates around the world and it is unclear whether the modern Fah bacteriophage
is the parent or daughter to the lysogenic phage. Fah was still produced into the 20th century, but
it is unknown whether it is still produced for veterinary and laboratory uses today (Minakhin et
al., 2005). While the host range of Fah is unknown, at least to public databases, recently isolated
phage has demonstrated better discrimination than the gamma phage. A recent phage, AP50,
was able to lyse 111/115 B. anthracis strains (97%) and none of the 100 B. cereus strains, while
the gamma phage lysed 105/111 B. anthracis strains and is known to infect certain B. cereus
strains. It appears that although gamma is the oldest diagnostic phage, it may not be the best
suited for clinical testing (Sozhamannan et al., 2008).
In addition to the well-known Ba02 lysogenic phage, there are multiple phage that are
highly conserved in the majority of B. anthracis strains (Ganz et al., 2014; Gillis & Mahillon,
2014). These prophages and one non-sense mutation are what characterize B. anthracis from
many other closely related strains of Bacillus, especially the closely related B. cereus and B.
thuringiensis. While B. anthracis is noted for having a short vegetative state, it is hypothesized
that prophage help the host’s sporulation, vegetative soil lifecycle, infection of earthworms, and
overall fitness. As many as sixteen prophage may be found in B. anthracis, with other
investigations only counting seven Siphoviridae prophage and eight Siphoviridae lytic phage.
Other phage isolates have been found and more will likely be found in the future, as three new B.
anthracis phage were recently found in 2017, and every few years new phage for this species are
isolated (Alkalay, Sternberg, Coppenhagen-Glazer, & Hazan, n.d.; Ganz et al., 2014; Gillis &
Mahillon, 2014; Schuch & Fischetti, 2009).
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Adjunct therapy potential and possible concerns
Phage combined with antibiotics have the potential to be a cleaner, safer, cheaper, more
efficacious, and more specific alternative to simple antibiotic treatment alone. Phage and
antibiotics combined could be a powerful clinical tool. It could be postulated that if B. anthracis
phage were to work well as therapeutics, it would have already been low hanging fruit and
completed, but this is not the case as B. anthracis phage work has lagged behind that of most
other bacterial genera.
Phage are a more natural alternative therapy and may be a good option for those who are
reluctant to use traditional medications and drugs. Phage are cheaper as they are easily produced
and increased dosage does not always mean a drastic increase in cost (Ozkan et al., 2016). They
are more efficacious when used together with antibiotics than antibiotics alone, as the activity of
antibiotic resistance is separate from phage resistance and antibiotics and phage have distinct
modes of action (Gill et al., 2015; Qadir, 2015; Torres-Barceló & Hochberg, 2016b). Phage are
highly specific and are self-limiting; if the host is not present then neither will be the phage.
The self-limiting aspect of phage and the broad-spectrum aspect of antibiotics are
essential distinctions between phage and antibiotics. Antibiotics can provide a possible clearance
of infectious disease with unclear etiology, while phage have the unique specificity to treat an
infection and not destroy commensal flora (Chan et al., 2013). A myriad of concerns about
bacteriophage containing toxins or acting as nanoparticles with surface charges and possible
aggregation issues have been voiced. These concerns are less important when viewed in light of
how phage can be treated as nanoparticles in safety studies, how toxins can be screened, and the
fact that phage have been administered in many different ways at varying dosages for nearly a
century with little or no ill effects (Rhoads, 2009).
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The safety of phage will only increase with increased regulation, awareness, and phage
toxin testing. The benefits appear to outweigh any potential costs that are currently envisioned
(Deresinski, 2009; Endersen et al., 2014; Sulakvelidze, 2001). Any concerns about safety can be
worked through, and it appears that overall, phage administration is much safer and causes less
harm to patients than antibiotics. Alexandra Henein poses an intriguing question, “Considering
reports that phage therapy has been widely successful even when used as a last resort in
infections non-responsive to antibiotics, a question arises: Is it even ethical to continue not
pursuing phage therapy?” (Henein, 2013). Regulatory issues will likely be worked through as
phage trials show successes. Phage resistance will occur and may be overcome as more novel
phage are found and new cocktails pass safety concerns. Existing phage can likely be
manipulated in the lab to increase their host range or include novel endolysin genes. Although it
may appear to outsiders that novel scientific discoveries are decreasing with each passing year,
this could not be further from the truth. “Even as biodiversity seems to be everywhere under
threat or in retreat, scientists are discovering and naming new species at a greater rate than
anytime during taxonomy’s 250-year history” (Stutz, n.d.). This is true for plants, animals, and
microbial life---especially for phage.
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MATERIALS AND METHODS
Choosing pathogenic strains for testing
Importance of genetic profile
With around 89 strains of B. anthracis that are commonly considered the worldwide type
strains, and thousands more clinical isolates, it is difficult to choose a proper battery of strains for
testing (P Keim et al., 2000). It was imperative to choose a number of strains for testing that
would represent the extant genetic diversity of pathogenic B. anthracis, while also being
manageable for rigorous testing and regulatory compliance in the BSL-3 research environment
(Wurtz et al., 2014). The BYU Select Agent Archive has over 300 strains, and 88 of the 89 type
strains at the writing of this paper. Performing tests on eighty-eight of the 300 strains was not
technically viable and many of the results would likely be similar, as B. anthracis is relatively
genetically homogenous, even compared to other Bacillus species.
Justification of Selected Strains
In order for our investigations to be easily replicated, we used only type strains and no
clinical isolates. B. anthracis is grouped into three different branches, or groups: A branch, B
branch, and C branch (see Figure 2 and Table 1). All of our testing was done with isolates from
the A and B branches, with 11 distinct pathogenic strains, and with the non-pathogenic B.
anthracis Sterne strain, for a total of 12 diverse strains. Testing of a strain that represented the C
branch was not possible in time for this work, but it will be evaluated later in further
investigations that are already planned. The eleven pathogenic strains that were used in this work
are well known to represent the extant genetic diversity of B. anthracis in the A and B branches
(Pilo & Frey, 2011; Van Ert et al., 2007).
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Figure 2. Figure and data by Van Ert et al. showing the genetic tree of the A and B groups tested. One
C group strain is also shown. Stars and circles represent strains and red arrows designate strain
relatedness. The genetic study was performed through SNP typing.
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Table 1. Table and data by Van Ert et al. showing the SNPs between the various strains. The
Lineage/Group column and Type Strain column correlate with circles and stars in Figure 2, which
represent the type strains used in our tests.

Phage isolation and screening
Sampling
Soil samples were taken across three states in the Western United States: Idaho, Utah,
and Nevada. All samples were fine soil samples except for sample 16, which consisted mostly of
wood chips. Samples came from rural, urban, and suburban environments. A description of these
samples and their locations is shown in Table 2 and Figure 3. Soil was taken beneath the grass
line and any foreign objects removed. Soil sample size was approximately 10g and these were
stored in sealed plastic bags without temperature control. After transportation to the lab, samples
were kept at ambient temperature in lab drawers until processed.
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Table 2. Names and locations of the various soil samples used in this study. The number in the sample
# column was used as an identifier during spot testing in the BSL-3 laboratory. The sample name also
corresponds to the phage names.
Sample #

Name of Sample

Location of Sample

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

R House 2
RC2
MILO
Timpview
GMA House
Moms Garden
Lehi Park
Backyard GMA
Gutter
Kate 2
Duck Pond
Ryan’s Corner
Harvey Fletcher
Rock Canyon
FOB
Temple
Wayne
Elko Tree
Nate2
4NSE

21
22
23

Lacey
Elko Garden
Marb

Elko, NV
Elko, NV
Rexburg, ID
Provo, UT
Lehi, UT
Rexburg, ID
Lehi, UT
Lehi, UT
Provo, UT
Lamoille, NV
Provo, UT
Provo, UT
Provo, UT
Provo, UT
Provo, UT
Provo, UT
Lamoille, NV
Elko, NV
Lamoille, NV
Provo, UT
Rexburg, UT
Elko, NV
Provo, UT
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Figure 3. The approximate locations where each soil sample was taken. Phage isolated from each
location are listed in parentheses. Stars represent different cities or towns where samples were taken.
RED, Rexburg. ORANGE, Elko. BLUE, Lamoille. GREEN, Lehi. BLACK, Provo.
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Assays using the Sterne strain
Enrichment Culture:
The following procedure was used to enrich for B. anthracis-specific phage:
1. Add 1ml B. anthracis Sterne (overnight culture) to 150ml flask
2. Add 10 ml LB broth to flask
3. Add 1g soil sample to flask
4. Incubate at 30 degrees Celsius for 2 days in shaking incubator
Filter and Plate enrichment culture:
The following procedure was used to visualize B. anthracis-specific phage:
1. 10 ml of enrichment culture was placed in a 15ml tube
2. Tube was centrifuged for 50 min at 4,000 rpm
3. Filter sample with .45um filter and syringe into new 15ml tube
4. Put 0.5ml B. anthracis Sterne culture in a red cap tube
5. Infect with 5 ul of filtered enrichment suspension
6. Incubate for 45 min at room temp
7. Plate with 5ml top agar
8. Let set (approximately 2 hours)
9. Place in 30-degree Celsius incubator for 48 hours
Plaque Purification Protocol:
The following procedure was used to purify each B. anthracis-specific phage:
1. Put 200 ul LB broth in a microcentrifuge tube
2. Pick plaque with pipette tip
3. Place pipette tip in the microcentrifuge tube with broth and mix
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4. Put 0.5ml B. anthracis Sterne culture in a red cap tube
5. Infect with 50 ul of plaque solution
6. Incubate for 45 min at room temp
7. Plate with 5ml top agar
8. Let set (approximately 2 hours)
9. Place in 30 degree Celsius incubator for 48 hours
High titer Lysate Protocol:
The following procedure was used to make and verify a high titer lysate for B. anthracis-specific
phage:
1. Put 1 ml B. anthracis Sterne culture in a 150 ml flask with 10 ml LB
2. Pick plaque from plaque purification plate with pipette tip
3. Infect B. anthracis in flask with the plaque
4. Incubate for 2 days at 30 degrees Celsius in shaking incubator
5. Centrifuge and Plate High Titer Lysate:
6. Put 10 ml of high-titer lysate (HTL) in 15ml centrifuge tube
7. Centrifuge for 50 min at 4,000 rpm
8. Filter with 0.45um filter and syringe
9. Put 180 ul LB broth in 3 micro centrifuge tubes
10. Do serial dilution starting with 20 ul filtered HTL (10 fold dilutions)
11. Plate dilutions 1, 2, and 3 with 5 ml top agar
12. Let set for 2 hours
13. Place in 30-degree Celsius incubator for 48 hours
14. Count plaques on plate for titer
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Phage Digest
In order to show genetic differences of the phage, a restriction enzyme digest was performed.
The restriction enzyme HindIII was used according to the following procedure:
1. Add 2 microliters of CutSmart and 17 microliters of DNA to a microcentrifuge tube and
mix well
2. Add 1 microliter of HindIII enzyme
3. Incubate for 1 hour at 37 degrees Celsius
4. Run digest on 1% agarose gel for 40 min at 150V
5. Visualize gel
Electron Microscopy
Bacteriophages are the most abundant biological entity on the planet and likely
contaminate many electron microscopy (EM) samples by accident. In our work, we were trying
to visualize only bacteriophage. Once a phage had been properly isolated through plaque assays
and a concentration of 107 plaque forming units (PFU) per milliliter had been obtained, electron
microscope images were taken for classification and measurements. While the process of
preparing a sample seems rather easy, if not done precisely, images will be low quality and not
viewable. The steps in this process were as follows:
1. Measure 0.2 grams of uranyl acetate in a glass contained scale on a weigh boat
a. Glass contained scale is used because of the danger of the uranyl acetate
2. Mix the uranyl acetate with 10 ml double distilled water in 15ml tube by shaking
a. Mixing the powder with the water allows the uranyl acetate to become
aqueous, which is necessary for this process
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b. Important: Steps 2-10 were done under a fume hood because uranyl acetate is
a hazardous material
3. Pipette a dot of 10 microliters of uranyl acetate onto Parafilm using a p 20 pipetteman
4. Pipette a dot of 10 microliters of bacteriophage sample next to the uranyl acetate
5. Remove a single grid from the grid holder using tweezers. IMPORTANT: only touch
the tweezers to the outer edge of the grid so the grid is not damaged

Figure 4. A simple schematic outlining steps 6-10 in the EM sample preparation protocol.

See Figure 4 for a schematic representing steps 6-10.
6. Place it in the bacteriophage sample dot for 2 minutes (completely submerged)
a. This is done to allow the bacteriophages to remove themselves from solution
and stick to the material on the grid
7. Take the grid out of the sample and run 300 microliters of double distilled water over
the grid slowly using a p 1000 pipette-man, catching runoff with a paper towel.
IMPORTANT: place the tip of the pipette close to the edge of the grid, but do not
touch it to the grid
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a. This is done to take off any excess material and remove any film that attached
to the grid
8. Place the grid in the uranyl acetate dot for 1 minute
a. This allows the uranyl acetate to attach to the bacteriophage, allowing for
visualization in the microscope (it acts as a negative stain)
9. Take the grid out of the uranyl acetate dot and blot the excess by lightly touching the
edge of the grid to a paper towel
a. This allows excess uranyl acetate to be removed, thus providing less exposure
to hazardous material and a cleaner image
10. Place the grid back into the grid holder
a. This allows one to keep track of the grid and not touch the samples, which
could ruin them.
11. Write down which sample was put into which column on the grid holder.
a. This allows the technician to connect the electron microscope image to the
sample.
12. Take sample to Electron microscopy specialist to run samples. All samples were run
on a Thermo Fisher Scientific Helios Nanolab 600 operated in STEM mode.
BSL-3 phage testing
Growing virulent B. anthracis strains
Virulent B. anthracis strains were grown in containment at all times per CDC regulations.
Compliance to all policies and procedures concerning BSL-3 select agents was followed strictly.
Strains were taken from freezer stocks and streaked for isolation using 10 L sterile inoculation
loops (Greiner Bio-One North American 200mm). LB agar plates were used. Following
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successful isolation of single colonies, stock plates were maintained at 4 degrees Celsius for 2
weeks. Isolates were grown at 37 degrees Celsius and double-bagged in plastic bags. Twelve
hours yielded miniscule, but visible, colonies on LB agar. A full day’s growth at 37 Celsius
yielded larger colonies. All work was started with B. anthracis colonies that were incubated at
least 18 hours.
Spot testing
Spot testing is an essential technique used to quickly and easily scan various phage
against a single host strain. Most spot tests are later confirmed by plaque assay analysis, which is
the gold standard for showing true phage infection. The steps for spot testing are outlined below:
1. Gather 11 strains of B anthracis: A34, A39, A102, A158, A193, A293, A402, A442,
A462, A488, A489 and B. anthracis Sterne.
2. Grow B anthracis strains from an isoplate in a 50 mL conical tube overnight or a 250 mL
glass flask. Place on shaker at 200 RPM overnight. If growing in a flask, use a cotton
stopper to allow air access. Double bag the flask or conical tubes while still allowing
passage of air.
3. Add 0.5 ml of overnight culture to a 15 mL conical tube
4. Add 5 mL of top agar (LB broth with agar)
5. Take mixture of top agar and bacteria and carefully pour onto petri dish partially filled
with set agar
6. Wait a few minutes for the agar to set
7. Spot 2 10 uL drops of phage (23 distinct viruses were tested) onto a quarter of each plate.
Each plate was typically inoculated with 8 drops.
8. Wait 12-24 hours and check plates for successful infection
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9. Analyze plates in hood by looking for clear plaques where spots were dropped
10. After recording data, dispose of plates in large ziplock bags. If culture was grown in a
flask, sanitize with 3% peroxyacetic acid or 0.65% bleach and remove from hood and
autoclave. If grown in 50 mL conical tube, tightly twist tube top and dispose in biohazard
bin and autoclave.
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RESULTS
Phage Identification and Characterization
Testing phage on Sterne strain
A phage enrichment was performed for each of the twenty-three soil samples shown in
Table 2 and Figure 3. After enrichment, the cultures were plated on B anthracis Sterne strain
under BSL-2 conditions. Figure 5 shows multiple plaques on B. anthracis Sterne from the
enrichment culture of the Wayne sample.

Figure 5. Phage plaques from the enrichment culture of the Wayne sample from Lamoille, NV

grown on B. anthracis Sterne. The plaques shown were picked and re-isolated until plaque
morphology was consistent.
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After successful infection from an enrichment culture, virus was purified by following
the procedures in the plaque purification protocol in the Materials and Methods section. The
plaques were then re-isolated until plaque morphology gave consistent and reliable results. After
this purification step was completed several times, it was assumed that that the virus was
monoclonal. Figure 6 illustrates an infection from a high titer lysate created from sample Elko
Tree.

Figure 6. Successful infection of Bacillus anthracis Sterne from a purified phage isolate of Elko Tree.
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Intriguingly, despite the overall genetic similarity between various strains of B. anthracis,
not all of the phage that infect a particular strain were able to be grown to the same titer. After a
high titer lysate is achieved, a titer is performed to determine phage concentration in PFUs.
Figure 7 shows the plating results from Step 11 of the high titer lysate protocol from Materials
and Methods.
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Figure 7. A phage titer as determined from plating serial dilutions of the high-titer phage suspension.
Shown from top to bottom are plates of the undiluted lysate and dilutions: 10^-1, 10^-3, 10^-5. The
colony growth shown on the undiluted and 10^-1 plates is likely rom germinated spores.
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Phage Differentiation
Phage isolation through BSL-2 testing on Sterne strain (Sampling, Isolation, Electron
microscopy, DNA isolation and restriction digests) were performed by Emily Hansen and
Rebecca Eardley (Grose Lab, Microbiology and Molecular Biology Department, BYU).
Genomic Digests
HindIII restriction digests were performed on DNA purified from each of the phage. Gels
from these digests are shown in Figures 8 and 9. This was done to quickly determine which
phage might be identical, so that duplicate sequencing could be avoided. From these
investigations, most phage appeared genetically distinct from each other, with the exception of
Ryans Corner and Harvey Fletcher depicted in Figure 9. There results will be confirmed by
complete sequencing and annotations that will be performed later.
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Figure 8. A gel showing the HindIII digestions of various phage genomes isolated in this work. From
left to right: 1. DNA ladder, 2. Duck pond, 3. Kate 2, 4. Lacey, 5. 4NSE, 6. Rock Canyon, 7. Lehi Park,
8. Wayne, 9. RC2 10. Temple, 11. GMA house
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Figure 9. A gel showing the HindIII digestions of various phage genomes isolated in this work. From
left to right: 1. R house, 2. Milo, 3. Timpview, 4. Mom’s Garden, 5. Backyard GMA, 6. Gutter 7. Ryans
Corner, 8. Harvey Fletcher, 9. FOB, 10. Elko Tree, 11. Nate 2, 12. Elko Garden, 13. DNA ladder. From
the picture lanes 7 and 8 (Ryans corner and Harvey Fletcher) appear highly related.

Electron Microscopy
Electron microscopy was used to document the morphology of the phage involved in this
study. Two images of different phage are shown in figures 10 and 11, illustrating phenotypically
distinct phage capable of infecting B. anthracis.
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Figure 10. R House 2 phage sample analyzed by electron microscopy. A structure typical of the
Siphoviridae is shown.
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Figure 11. Backyard GMA phage viewed with electron microscopy at 500,000x magnification. Similar
to figure 10, the structure of a Siphoviridae was observed.

Spot Tests
Spot tests were performed on Sterne and virulent B. anthracis strains. A summary of the
spot test results is shown in Table 3. Most of the spot tests performed were done with 8 spots,
two per phage, testing four phage against a single bacterial strain. Images of typical spot tests are
shown in Figures 12, 13, 14, and 15.
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Table 3. Results from the spot test assays for 23 phage tested against 11 virulent B. anthracis isolates and the Sterne strain. Negative for
infection (shown in Red), positive for infection (no color), and weak positive (depicted in yellow). Xs are shown for assays that were repeated
at least 12 or more times.

Figure 12. A typical spot test with eight drops, two drops per quadrant. This is a positive control plate
showing that this phage infects the Sterne strain of B. anthracis with phage 13 (Harvey Fletcher), 14
(Rock Canyon), 15 (FOB), 16 (Temple). Varying levels of infection are evident.
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Figure 13. A typical spot test using the virulent strain of B. anthracis A193 with phage 1 (R House 2), 6
(Mom’s Garden), 7 (Lehi Park), and 11 (Duck Pond). Similar to Figure 12, different phage expressed
different infection characteristics.
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Figure 14. A spot test representing a weak positive infection of virulent B. anthracis strain A462 by
phage 19.
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Figure 15. Same spot test and petri plate as Figure 14, but observed from the other side of the plate,
showing how some weak positive results are difficult to see from both sides of the agar.
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DISCUSSION
Purpose
The purpose of this study was to identify phage that could infect virulent strains of B.
anthracis and to date, only a handful of phage have been described that are capable of infecting
this pathogen. (Alkalay et al., n.d.; Gillis & Mahillon, 2014; Minakhin et al., 2005; Sozhamannan
et al., 2008). With a renewed interest in phage therapy, such phage could prove to be clinically
useful. B. anthracis is easily weaponized, and has been used in bioterrorism attacks (JończykMatysiak, Kłak, Weber-Dąbrowska, Borysowski, & Górski, 2014; H. Kikkawa, Fujinami,
Suzuki, & Yasuda, 2007; H. S. Kikkawa, Ueda, Suzuki, & Yasuda, 2008; Sternbach, 2003).
Preventive measures, such as large scale antibiotic prophylaxis can be expensive, as was seen in
the 2001 anthrax attacks in the U.S. Phage are useful in fighting bacterial infections, as they are
non-toxic to the larger environment, specific to their targets, replicable, inexpensive, and
promising, as research is only starting to come forward after being abandoned for decades in
favor of antibiotics (Abedon, 2015; Brüssow, 2012; Gill et al., 2015; Torres-Barceló &
Hochberg, 2016a; Wittebole et al., 2013). This work characterized phage found to infect the nonpathogenic B. anthracis Sterne strain using enrichment and plaque purification techniques. It
further discriminated among the phage found using genetic and phenotypic differences by
employing restriction digests and electron microscopy, and finally tested phage for infectivity
against a variety of virulent B. anthracis isolates in a BSL-3 laboratory using spot assays.
Phage Discovery
Phage discovery was completed in a BSL-2 lab before phage were tested in a more
regulated and technically challenging BSL-3 facility (Wurtz et al., 2014). Figure 5 depicts a
positive infection of B. anthracis Sterne using an enrichment culture from sample 17, Wayne.
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This image shows how phage discovery can successfully identify phage with a desired
specificity. Simple techniques are used to find phage and phage discovery can be a new and
inexpensive pathway to help fight antibiotic-resistant strains of bacteria (Allen et al., 2014;
Rahmani, Zarrini, Sheikhzadeh, & Aghamohammadzadeh, 2015; Torres-Barceló & Hochberg,
2016b).
There are an abundance of phage around us and they have a remarkable capacity to
control bacterial growth in many different environments (Abedon, 2009; H.-W. Ackermann,
1998; H. W. Ackermann, 2003). It is important to note that the concentration of phage in the
enrichment culture was likely low, as only a small and easily countable number of plaques were
produced on the plate. Therefore, enrichment cultures are unlikely to have a high enough titer of
virus to be truly efficacious for any clinical work. However, high titer lysates can be easily and
quickly prepared, as shown in Figure 7. The ability to prepare high titer lysates is absolutely
essential to achieving a therapeutic benefit in phage therapy (Sarker et al., 2012).
Comparing Figures 5 and 7 shows a clear quantitative difference between an enrichment
culture and a high titer lysate. The dramatic increase in PFUs is only possible by creating high
titer lysates. High titer lysates are better able to achieve therapeutic success, as they contain a
large enough number of phage to infect and destroy the target hosts (Ryan, Gorman, Donnelly, &
Gilmore, 2011). A high phage concentration is one of the most important aspects of any
successful phage therapy. If a phage is identified and it is impossible to amplify it to efficacious
levels, it will likely prove worthless in a clinical setting. The phage investigated in this study
could all be grown to high titers. Figure 7 shows the plates of a Wayne phage sample from a
high-titer lysate, plated undiluted, and diluted 10^-1, 10^-3, and 10^-5. Phage titers varied
among the phage, again showing that even with a monophyletic strain such as B. anthracis, the
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phage that infect it can be diverse and distinct. Figure 7 clearly shows that the HTL of Wayne
lyses the bacteria so completely that no individual plaques can be seen in the undiluted sample.
However, B. anthracis is able to form spores which seem more refractile to phage lysis (Walther,
2003).
It appears from the image that at a lower concentration of phage, more colonies from
what we believe to be germinated spores, are seen on the 10^-1 plate when compared to the
undiluted plate. It is intriguing that these colonies from spores are not as clearly seen on the 10^3 and 10^-5 plates. Perhaps better infectivity occurs at a lower concentration of phage. In any
case, little bacterial growth is seen on any of the plates until the 10^-5 dilution, where multiple
individual plaques on a lawn can be seen. The reason why bacterial colonies do not appear on the
10^-3 and 10^-5 plates may be because in these plates, there was greater amplification possible
for the phage. The higher relative concentration in the HTL plates may have killed all the
bacteria quickly enough that only spores were left, hence the higher concentration of colonies on
the undiluted plate. For the 10^-1 plate it would make sense that the colony count would be
lower, as greater amplification of phage was possible because the phage did not instantly kill all
the vegetative bacteria available.
Phage Discrimination
Phage discrimination is essential in phage biology. It is estimated that there are at least 10
different phage for every strain of bacteria (Rohwer, 2003). Phage are the most abundant
biological entity on the planet, and it is estimated that there are more than 10^31 phage causing
10^23 infections every second (Hendrix, 2003). With so many environmental phage for each
bacterial strain, it would be easy, albeit expensive, to sequence multiple phage. The concern is
that it is possible to over sequence and have enough sequence similarity to question the scientific
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significance of the data if the environmental phage are closely enough related. Phylogenetic
studies using EM data and genetic work done using restriction enzyme genome digests can better
help scientists make decisions on which phage to study in depth, using sequencing, annotation,
and other methods, without doing work that is redundant. Of the twenty-three phage used in this
study, only one did not produce a digest pattern: MARB sample 23. This was also the only phage
that was not able to infect the virulent strains. There are issues with this MARB phage that still
need to be worked out. This phage was harder to manipulate than the other phage in this study.
The only phage from the digestions that looked quite similar were Ryan’s Corner and Harvey
Fletcher (Figure 9, wells 7 and 8). These data seem to indicate that the other 21 phage are
different from each other and could be sequenced. Sequencing and gene annotations are currently
being performed on the phage in this study.
Electron microscopy is an essential technique in phage work and historically helped
prove that phage were in fact viruses (H. W. Ackermann, 2003). Phage can vary greatly in their
size and shape, but the phage we saw most often in our EM work belong to the Siphoviridae
family (long, non-contractile tails). These are the most common phage in existence, making up
over 60% of observed phage (Petrovski, Dyson, Seviour, & Tillett, 2012). We can see in Figures
10 and 11 that the viruses are most likely Siphoviridae from the tail and the head size and shape.
At the same magnification, it appears that R House 2 is a larger phage than Backyard GMA.
Spot Testing
Spot tests are a common way to determine host range and infection potential and do so in
a manner much quicker than plaque assays. Many recent papers have utilized spot tests to show
infectivity of phage on their respective hosts, with hosts that ranged from Methicillin resistant S.
aureus to Esherichia coli to Klebsiella pneumoniae, treating skin infections, foodbourne illness,
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and urinary tract infections, respectively (Askora, Merwad, Gharieb, & Maysa, 2015;
Rahimzadeh, Gill, & Rezai, 2017; Snyder et al., 2016; Sybesma et al., 2016). Despite prolific use
of spot testing in phage work and investigators insistence that spot tests are statistically similar to
plaque assays, it appears that spot tests likely overestimate host range and infectivity
(Champagne & Gardner, 1995; Mirzaei & Nilsson, 2015). Despite these significant concerns, our
investigations have presented the spot test data with full understanding and acceptance that
further work is necessary before infectivity and host ranges can be determined with full
confidence.
During the spot testing for these investigations, thousands of plates were spotted and
analyzed. Despite the need for plaque assay work in the future, the spot testing performed was
repeated a dozen times or more for most strains and phage and was generally consistent. Only a
few representative photos from hundreds were presented so that the processes used could be
comprehended. Figure 12 shows how four phage infected the positive control strain of B.
anthracis Sterne. From the picture, it is clear that the phage spots differed in turbidity. It
appeared that Rock Canyon did not infect as well as Harvey Fletcher, when looking at the spot
test turbidity. In quadrants 15 and 16, the phage FOB and Temple appear to have produced
greater lysis, with a zone of clearing that showed less bacterial growth inside the zone. Figure 13
showed clearly that despite the phage all being isolated from the Sterne strain before being
applied to a virulent strain of B. anthracis, all of the phage caused varying degrees of lysis.
From our analysis of spots on the Sterne strain, it became evident that rather than
characterize infection by a magnitude of infection such as ‘strong or weak’, a binary ‘infection or
non-infection’ was far more useful. A few outliers were noticed that truly showed consistent
weak infection. However, the main point of our investigations was simply to show infection vs.
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non-infection, regardless of the degree of phage lysis in the spot tests. Table 3 diagrams which
phage where able to infect which strain of virulent B. anthracis. The outliers which were
assigned the label of a “weak” infection were phage 17 (Wayne) infecting strain A402 and phage
19 (Nate 2) infecting virulent strains A462 and A488. Greater elucidation of phage host range
will be much more easily ascertained when rigorous plaque assays are performed at the same
stringent replication expectations that characterized the spot assay work in this investigation.
Positive infections were much easier to see compared to the few “weak positive”
infections. This may not be clear when viewing just one side of the plate, but was quite evident
when viewing all the images, especially Figure 15. Figure 13 shows four positive infections with
R House 2 (1), Mom’s Garden (6), Duck Pond (11), and Lehi Park (7). R. House 2 had the
strongest infection followed by Lehi Park then Duck Pond, and finally Mom’s Garden. Figure 14
shows a weak infection of strain A462 with phage 19. The image shows lysis that is difficult to
differentiate from the weakest infection (Mom’s Garden) shown in Figure 13. However, when
viewed from the front side in Figure 15, the infection of phage 19 into A462 is clearly not the
same magnitude as Mom’s Garden. Further testing will be needed to confirm or deny a
presumptive infection. Only infections that were consistent and replicable were counted. This
work, although important, is only the first part of a greater work which will substantiate the
preliminary findings derived from the spot tests. Despite, the drawbacks of this study, it is still
very important to identify phage that appear to show strong infection of virulent B. anthracis.
Summary and Future Directions
Twenty-three phage were found which were able to infect the Sterne strain of B.
anthracis. Genetic and morphological characterizations were performed through restriction
digests and electron microscopy, respectfully. Of these 23 phage, 22 showed activity against
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virulent strains according to our spot test data. While these findings set a strong basis for future
work, there is additional work that needs to be completed, namely, plaque assays, genome
sequencing, and inclusion of one B. anthracis strain that represents the “C” branch.
Plaque assays are much more definitive in their results and show substantial support that
there is true infection occurring (Hyman & Abedon, 2010 Mirzaei & Nilsson, 2015).
Bacteriocins and lysins present in the lysates used with spot tests can create ‘false positives’, as
can “lysis from without” or simply a high concentration of phage that is logarithmically higher
than the number of bacteria (Abedon, 2011). Plaque assays will be an important follow up to our
present work.
Genetic sequencing of these phage is already underway and annotations of the phage
genomes will be provided in the near future. The host range data, EM work, and restriction
digest data are only a partial description of the phage listed in this study. Finally, a small but
easily remedied issue with our study is that a representative of the C branch was not included in
our host range spot test assays. The difficult to acquire and newly discovered C branch is
represented by only one strain of the 221 strains of unique B. anthracis isolates in the study of
the phylogeny of B. anthracis (Van Ert et al., 2007). Only four C branch isolates are known, and
they do not express the marked pathogenic potential characteristic of the A strains. It is believed
that B (15% of known strains) and C strains (less than 0.5% of known strains) play a more
regional role in their environments, while A strains of B. anthracis are truly global in their scope
and impact. It is not clear if A strains possess greater fitness or if their worldwide distribution is
due to more stochastic processes. (Pearson et al., 2004). While missing a representative the C
branch strains in our analysis, as they are new to the research scene and not common in any
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anthrax outbreaks, this discrepancy is somewhat mitigated by their lack of historic importance in
bioterrorism research (Derzelle, Aguilar-Bultet, & Frey, 2016; Paul Keim et al., 2004).
Phage work is an exciting frontier with incredible growth potential in therapeutics, novel
phage discovery, and uncovering keys to better understand unknown underpinnings in molecular
biology. Although phage are the most abundant biological entity on the planet, much work is
needed to better elucidate phage/host interactions and how to bring phage therapy into the 21st
century (Petrovski et al., 2012). While our project identifying phage that can infect virulent B.
anthracis is far from complete, this work provides the structure to start new efforts that will
expand our knowledge of phage and B. anthracis alike, and provide additional opportunities to
showcase the diversity and importance of the microbial world.
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